THREDD
1.8.2024 10:01:31 CEST | Business Wire | Press release
Thredd, the rapidly expanding next-generation global payments platform, reports both industry-wide growth in fintech-led digital payments and the renewal of its partnership with Zilch, the world’s first ad-subsidised payments network (ASPN). This positive trajectory, coupled with recent product and market expansion, adds further momentum to Thredd’s leadership in modern payments processing.
“2024 continues to build on the robust foundation we established in 2023. Our clients, both new and old, are driving strong transaction growth, through a combination of market expansion and increasingly innovative financial services solutions,” said Jim McCarthy, Chief Executive Officer at Thredd. “The expansion we have seen is a testament to their resilience and the demand for new payments use cases in both B2C and rapidly growing B2B payments.”
In February, Thredd noted an atypical early-year uptick in debit and prepaid transactions across several business verticals. This growth has continued in BNPL (+56% YTD), corporate spend management (+74%) and B2C Retail (+28%) transactions.
Success Story: A Growing Partnership with Zilch
BNPL shows no signs of slowing. Since January 2022, Thredd’s clients in this space have seen transaction volumes grow by 175%, reflecting the growing importance of instalment payment options at the point of sale. Leading the way is Zilch, with whom Thredd has recently renewed, retaining the business in a hotly contested evaluation against larger US and European-based competitors. Zilch, one of the world’s fastest growing BNPL providers and a true innovator in this space, offers consumers repayment optionality combined with cashback and rewards through a regulated and unique business model where they uniquely combine the world's $1 trillion dollar advertising with personal credit.
The Zilch-Thredd partnership combines payment network connectivity and transaction management expertise that allows Zilch to focus on its key business objectives of driving billions in commerce to retail partners on ASPN while delivering hundreds of millions of savings, discounts and rewards to their growing customer base. The two companies work collaboratively on product and service innovations to improve the experience of over 4 million customers using Zilch.
“Working together with Zilch since their inception, we’ve had the privilege to be a part of their incredible growth,” said Jim McCarthy. “We sincerely appreciate the trust that Zilch has put in Thredd to help them reach more than 10 million monthly payments, and are looking forward to continuing our close working relationship to help Zilch set further growth records. We’ve seen Zilch grow from zero to over 4 million registered users, gain industry-leading utilisation rates where their customers pay on their platform 100 times a year on average and over $3bn in sales using Thredd as a trusted partner”
Philip Belamant, CEO and Co-Founder of Zilch commented: “Thredd has always allowed us to focus on delivering an unparalleled service to our customers. With Jim at the helm as the driving force of their talented team, it gives us confidence that Zilch will continue to have a reliable and secure payments link in the background as we continue in our next phase of rapid growth and roll-out of innovative products for our customers.”
Rakesh Harji, Chief Operating Officer at Zilch, added: “From inception, our partnership with Thredd has been crucial in building the core infrastructure to securely handle over 10 million monthly transactions and maintain a seamless user experience. Thredd have been with us from zero to over 4m customers and we look forward to continued innovation on product and services as we scale the business and expand our offering to our highly active customers who trust Zilch for their increasing daily lifestyle payment needs.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801143571/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
